Background
Genentech, the pioneering biotechnology company, held patents on recombinant human growth hormone (hGH) — one of the first approved recombinant therapeutic proteins. The claims at issue were broadly drafted and sought to cover any recombinant production of human growth hormone, while the specification described a specific recombinant production method using a particular bacterial expression system. Novo Nordisk, a Danish pharmaceutical company, had developed its own recombinant hGH production method and sought a declaration that Genentech’s broad claims were invalid for failing to satisfy the written description requirement of § 112.
The dispute illustrated the classic tension in biotechnology patent prosecution between patent applicants seeking broad claims that cover all possible approaches to an invention and the written description requirement that limits claims to what the specification actually describes.
The Court’s Holding
The Federal Circuit affirmed that Genentech’s broadest claims were invalid for insufficient written description. The court held that the written description requirement demands that the specification actually describe the full scope of what is claimed — the inventor must have “possession” of the entire scope of the claims at the time of filing. Claims that are broader than what the specification describes are invalid for lack of written description, even when the inventor is a pioneer in the field and even when later work demonstrates that the broader claim scope is achievable.
The court rejected Genentech’s argument that its pioneering status in recombinant hGH production entitled it to broad claims covering all methods of producing recombinant hGH — noting that the written description requirement is not relaxed for pioneer inventions and that the scope of claims must remain commensurate with what was actually described.
Key Takeaways
- The written description requirement limits biotechnology patent claims to the scope actually described in the specification — claims cannot be broader than what the inventor had possession of and described at the time of filing, regardless of the inventor’s pioneering status in the field.
- Broad genus claims in biotechnology (claiming all methods of producing a protein, all antibodies against an antigen, all sequences encoding a polypeptide) are particularly vulnerable to written description challenges when the specification describes only specific examples within the broader genus.
- Pioneer status in a technology field does not provide immunity from written description requirements — even the first inventor of a biotechnology method is limited to claiming what the specification actually describes, not the full genus that subsequent research might later demonstrate is achievable.
- Genentech v. Novo Nordisk is an early articulation of the written description doctrine that later courts applied to limit genus claims in antibody patents (Amgen v. Sanofi), genetic sequence patents (Regents of UC v. Broad), and other broad biotechnology claims.
Why It Matters
Genentech v. Novo Nordisk was an important early Federal Circuit decision establishing the rigor of written description requirements for biotechnology patents — a category of patents where the gap between what was specifically achieved and what was broadly claimed often created significant patent scope disputes. The case established that Genentech’s groundbreaking achievement in recombinant hGH did not entitle it to claim all methods of recombinant hGH production in perpetuity.
The written description doctrine articulated in Genentech v. Novo Nordisk has become increasingly important as biotechnology patents increasingly claim broad functional genera — all antibodies with a particular function, all gene sequences encoding a particular protein, all methods achieving a particular therapeutic result. The Federal Circuit’s consistent application of this doctrine (through Regents v. Lilly (1997), Enzo Biochem (2002), and Amgen v. Sanofi (2021, 2023)) has become one of the most important constraints on the scope of biotechnology patent protection — limiting the degree to which early biotech inventors can claim the entire landscape of a newly discovered class of therapeutic targets or biological agents.